Omni Nutraceuticals
This article was originally published in The Tan Sheet
Executive Summary
Firm has not specifically discussed use of split labeling for its Inholtra Joint Pain line of analgesic/glucosamine combo products with FDA, as reported by "The Tan Sheet" (July 16, p. 4). Rather, Omni notes it was anonymously represented by law firm Sidley & Austin, which presented FDA reps with a mock-up version of a split label